Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of ...

The new school was designed by working with national industry leaders who examined the needs in public health.

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

The most common cardiovascular killer in maternal medicine is also among the most misdiagnosed. Peripartum cardiomyopathy ...

Researchers from Indiana University (IU) and Makerere University in Uganda suggest that high uric acid concentrations ...

In an editorial, J. Mocco, MD, of Mount Sinai Health System in New York City, characterized the DISTAL and ESCAPE-MeVO ...

The 94-patient cohort had an overall response rate ... and co-authors in the New England Journal of Medicine. "In this study, talquetamab plus teclistamab had a similar safety profile to each ...

For people with atrial fibrillation (Afib), investigational abelacimab proved to be a potent dual factor XI/XIa inhibitor ...

A new study comparing blood samples from menopausal women pre- and post-COVID shows that those with elevated leukocyte (white ...

As many as 12 suspected Ebola virus cases have been reported in Democratic Republic of the Congo ’s (DRC’ s) Equateur ...

Among patients with COPD who experienced an exacerbation, the risk for cardiovascular events was highest in the following 2 weeks and stayed elevated more than 1 year after, according to study results ...

The researchers found that imlunestrant prolonged progression-free survival (PFS) when compared to standard care in patients with ESR1 mutations, but there was no PFS benefit observed in the overall ...